Abstract Details

Title The Neurology® Resident & Fellow Section (RFS): Performance, Internationalization, and Recent Challenges

Topic Education, Research, and Methodology

Presentation(s) S34 - Research Methodology and Education (1:24 PM-1:36 PM)

Poster/Presentation
Number 003

Background

The trainee-run Neurology® RFS was started in 2004. There have been several adjustments to expand the global reach of the RFS. However, recent changes from the COVID-19 pandemic and a new requirement for informed consent for all case-based manuscripts may negatively affect authors.

Objective To (1) determine the proportion of international submissions and accepted manuscripts in the Neurology® Resident & Fellow Section (RFS); (2) identify the most popular subsections; (3) assess the impact of the COVID-19 pandemic and introduction of consent to disclose for case-based submissions.

Design/Methods We analyzed submissions and acceptance rates by year and classified them by origin as US or international. We assessed whether the changes described above affected the overall submission rate (comparing 1.5 years before/after March 11, 2020 for COVID-19 and 6 months before/after new consent requirement).

Results Between 2005 and 2020, the RFS received 6,822 submissions and 6,522 (42% from US authors) were included in this analysis. Of them, 1,904 manuscript were accepted (51% from US authors). Over this period, acceptance rates declined from 67% to 17%. The proportion of manuscripts submitted from outside the US has increased from 50% (2004) to 61% (2020) (p<0.0001). Acceptance rates for US and international papers in 2005 were 73% and 60%, respectively (difference: 13.3%; 95%-CI -19.5-21%). In 2020, they decreased to 20% and 15%, respectively (difference: 4.73%; 95%-CI 0.09-9.59%). The most popular subsection was Teaching NeuroImages, constituting 39% and 58% of submissions from US and international authors, respectively. The number of submissions increased by 28% in the 18 months after COVID-19 was declared a global pandemic (1,594 vs. 1,241 in the preceding 18 months). After the consent requirements went into effect, we did not see a decline of submissions.

Conclusions The RFS has become increasingly international in terms of submissions, acceptance rate, and participation of members located outside the US.

Authors/Disclosures
Guillermo R. Delgado-Garcia, MD, MSc (University of Calgary - Alberta Health Services) PRESENTER	Dr. Delgado-Garcia has received research support from Consejo Nacional de Ciencia y Tecnologia (Mexico). Dr. Delgado-Garcia has received research support from Consejo Nacional de Ciencia y Tecnologia (Mexico). Dr. Delgado-Garcia has a non-compensated relationship as a Editorial Team Member with Neurology Resident & Fellow Section that is relevant to AAN interests or activities. Dr. Delgado-Garcia has a non-compensated relationship as a Editorial Board Member with Brain and Life en Espanol that is relevant to AAN interests or activities. Dr. Delgado-Garcia has a non-compensated relationship as a Editorial Board Member with Neurology Clinical Practice that is relevant to AAN interests or activities.
Whitley W. Aamodt, MD (University of Pennsylvania)	Dr. Aamodt has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology.
Jose G. Merino, MD, MPhil, FAHA, FAAN (MedStar Georgetown University Hospital - Dept of Neurology)	The institution of Dr. Merino has received personal compensation in the range of $100,000-$499,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. An immediate family member of Dr. Merino has stock in NovoNordisk. An immediate family member of Dr. Merino has stock in Sanofi. An immediate family member of Dr. Merino has stock in United Healthcare. An immediate family member of Dr. Merino has stock in Novartis. An immediate family member of Dr. Merino has stock in Medtronic.
Roy E. Strowd III, MD, FAAN (Wake Forest School Of Medicine)	Dr. Strowd has received personal compensation for serving as an employee of Kaplan. Dr. Strowd has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Monteris Medical, Inc. Dr. Strowd has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novocure. Dr. Strowd has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. The institution of Dr. Strowd has received research support from Southeastern Brain Tumor Foundation. The institution of Dr. Strowd has received research support from Jazz Pharmaceuticals. The institution of Dr. Strowd has received research support from National Institutes of Health. The institution of Dr. Strowd has received research support from Alpha Omega Alpha. The institution of Dr. Strowd has received research support from American Board of Psychiatry and Neurology. Dr. Strowd has received publishing royalties from a publication relating to health care. Dr. Strowd has received publishing royalties from a publication relating to health care.